ClinicalTrials.gg
CompletedNCT03709927Updated Mar 6, 2019

4-way Crossover QT Evaluation in Healthy Subjects

A Phase 1 interventional study of ZTI-01 and Moxifloxacin 400mg in Cardiac Repolarization in Healthy Subjects, sponsored by Nabriva Therapeutics AG. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-06.

Sponsored by Nabriva Therapeutics AG · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2018, 8 years 7 months ago, and no results have been posted to the registry.
  • Registered 3 months after the study started (first participant enrolled Jan 2018, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate if ZTI-01 (fosfomycin for injection), an investigational drug being developed to treat people with complicated urinary tract and kidney infections, has any effect on the electrical activity of the heart.

Read the detailed description

This is a single-center, randomized, placebo-controlled, four-period, cross-over study to assess the effect of single-doses of ZTI-01 at therapeutic (T) and supratherapeutic (ST) plasma concentrations on the QTc interval versus placebo (P) and an open-label moxifloxacin (M) control (400 mg PO).

Assessment of safety data will include changes from baseline in vital signs and laboratory parameters, infusion site reactions, adverse events and clinically significant changes from baseline in 12-lead ECG parameters.

02

Conditions studied

  • Cardiac Repolarization in Healthy Subjects
03

In context

Lead sponsor

Nabriva Therapeutics AG is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • physically and mentally healthy volunteer
  • a man or woman, 18 to 55 years of age
  • a woman of using / negative pregnancy test or a woman of non-childbearing potential
  • males with female partners of childbearing potential agree to use contraception
  • 19.0 to 32.0 kg/m2; weight of at least 60.0 kg at Screening
  • willing to complete the required 4 study periods

Exclusion criteria

Exclusion Criteria:

  • History or evidence of cerebrovascular or cardiac disease
  • Uncontrolled hypertension
  • Electrographically significant abnormalities on
  • medical history (PI assessment)
  • Clinically relevant lab abnormalities (PI assessment)
  • Calculated \< 60.0 mL/min/1.73m2 based on CKD-EPI 2009 equation
  • Abnormal liver tests
  • Positive serology , , or Hep C virus
  • , hematocrit, electrolytes below lower limit of normal
  • Received any hepatic or renal clearance altering agents within 30 days
  • History of allergy or to drugs with clinically significant reaction
  • Unwilling to refrain from strenuous exercise from 7 days prior to admission until discharge
  • Uses any prescription drug / OTC, within 7 days prior to admission, or 14 days prior to Admission if the drug is a potential inducer or inhibitor of cP450, or 5 half-lives (if longer), or subject continued use of a prescription drug / OTC medication (except )
  • Scheduled to have surgical procedure during study
  • Acute illness that has resolved in less than 14 days, or has had a major illness, or hospitalization within 1 month
  • Unwilling to abstain from ingestion of caffeine or xanthine-containing products 96 hours prior and throughout study
  • Unwilling to abstain from alcohol beginning 72 hours prior and throughout study
  • History of high alcohol consumption within 6 months
  • History of drug abuse (in the previous 3 years) or positive urine drug screen
  • Used tobacco-containing products within 6 months or has a positive cotinine
  • Consumed grapefruit and/or grapefruit juice within 14 days and throughout study
  • Consumed other fruit juices within 72 hours and throughout study
  • Consumed cruciferous vegetables or charbroiled meats within 7 days and throughout study
  • Donated plasma or blood within 30 days or has a history of blood donation of > 450 mL within 3 months
  • Used any drug within 30 days
  • Previously received fosfomycin
  • Deemed by the Investigator to be inappropriate for this study
  • Participated in another clinical study within 30 days (or 5 half-lives)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Therapeutic ZTI-01 6 g IV

    intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 6g

    Drug: ZTI-01

  • Experimental
    Supra-therapeutic ZTI-01 12 g IV

    intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 12g

    Drug: ZTI-01

  • Active comparator
    moxifloxacin 400 mg PO

    oral moxifloxacin 400mg film coated tablets - Avelox(TM)

    Drug: Moxifloxacin 400mg · Other: Placebo IV

  • Placebo comparator
    Placebo IV

    IV 0.9% normal saline solution

    Other: Placebo IV

Interventions

  • DrugZTI-01

    6g IV fosfomycin

    Also known as: IV fosfomycin, fosfomycin disodium, fosfomycin for injection

  • oral moxifloxacin (Avelox 400 mg) + IV normal saline (Placebo)

    Also known as: Positive control

  • OtherPlacebo IV

    IV Placebo (0.9% Normal Saline)

    Also known as: Negative Control

06

What researchers measure

Primary outcomes

  1. Effect of ZTI-01 at the therapeutic and supra-therapeutic plasma concentration on cardiac repolarization expressed by QT interval

    Determine the change-from-baseline QTc (ΔQTc) when compared with placebo, and moxifloxacin (400 mg PO)

    Time frame: 24 hour Holter ECG at Baseline (Day -1) & day of dosing (Day 1) in each of 4 periods. 10 replicates per time point at 13 timepoints: pre-dose: 60, 45 and 30 minutes; after the start of infusion: 0.5, 1 (end infusion), 1.25, 1.5, 2, 3, 4, 8, 12, & 24 hrs

Secondary outcomes

  1. Treatment emergent adverse events (TEAEs)

    Number and percentage of subjects reporting a TEAE overall and by treatment

    Time frame: From Day 1 start of dosing up to Day 36-38 (final follow up visit)

Other outcomes

  1. Cmax after a single dose IV administration of ZTI-01 6g and 12g

    Maximum plasma concentration Cmax (microg/mL) by dose (6g and 12g)

    Time frame: Cmax at end of 1-hour single dose infusion

07

Study locations

1 site
  • Pharmaron
    Baltimore, Maryland 21201, United States
08

References and documents

Individual participant data

Plan to share: Undecided — final report, publication

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Apr 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2018
First posted
Oct 17, 2018
StartActual
Jan 11, 2018
Primary completionActual
Apr 12, 2018
CompletionActual
Aug 21, 2018
Last update
Mar 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03709927
Lead sponsor
Nabriva Therapeutics AG
Responsible party
Sponsor
First posted
Oct 17, 2018
Start date
Jan 11, 2018
Primary completion
Apr 12, 2018
Completion
Aug 21, 2018
Last update
Mar 6, 2019

Study contacts

Evelyn J Ellis-Grosse, PhD
study chair · Chief Scientific Officer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fosfomycin sodium

Start the discussion